Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
The Stock That Tripled in a Day
06:55am, Tuesday, 07'th Mar 2023
Texas-based biotechnology company Reata Pharmaceuticals, Inc. (NASDAQ:RETA) lulled shareholders to sleep in 2022. The news flow was light, the trading pattern sideways and volume virtually nonexistent
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
06:40am, Monday, 06'th Mar 2023
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and comm
The quality of your clinical data drives everything, says Reata Pharma CEO Warren Huff
02:58pm, Thursday, 02'nd Mar 2023
Warren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval.
Why Reata Pharmaceuticals Stock Skyrocketed This Week
01:42pm, Thursday, 02'nd Mar 2023
A major regulatory approval lit a fire underneath Reata's shares this week.
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug
08:17am, Thursday, 02'nd Mar 2023
Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product
Cytokinetics will seek international approval for drug following FDA rejection, says CEO Robert Blum
03:10pm, Wednesday, 01'st Mar 2023
Cytokinetics President and CEO Robert Blum joins 'Power Lunch' to discuss the FDA's rejection of the company's heart failure drug, how FDA approval increases shareholder value and future treatment pla
Pharma Stock Surges After FDA Approves Treatment
02:30pm, Wednesday, 01'st Mar 2023
The shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) are up 178.5% at $86.81 this afternoon, after U.S. Food and Drug Administration (FDA) approved the drugmaker's Skyclarys treatment for Friedre
Reata Pharmaceuticals wins key FDA approval for rare disease treatment Friedreich's ataxia, sending shares soaring
12:23pm, Wednesday, 01'st Mar 2023
Biopharma company Reata Pharmaceuticals Inc (NASDAQ:RETA) was in the spotlight on Wednesday after a key approval from the US Food and Drug Administration (FDA) sent its stock soaring. The company ann
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
09:09am, Wednesday, 01'st Mar 2023
Markets are trying to rise, and these companies are helping out.
Reata's stock jumps 175% in premarket trading after FDA approval
08:06am, Wednesday, 01'st Mar 2023
Shares of Reata Pharmaceuticals Inc. RETA soared about 175% in premarket trading on Wednesday, the day after the Food and Drug Administration approved Skyclarys, a treatment for Friedreich's ataxia, a
Here are U.S. stocks in focus ahead of Wednesday's trading session:
Reata Soars on Approval for Rare Disorder Drug. Its Pipeline Impresses Analysts.
07:14am, Wednesday, 01'st Mar 2023
The FDA approves the pharmaceutical company's treatment for Friedreich's ataxia, which Citi analysts expect to generate peak U.S. revenue of around $1.2 billion.
Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval
06:03pm, Tuesday, 28'th Feb 2023
Reata Pharmaceuticals won FDA approval for its neurological disease treatment late Tuesday, shortly after RETA stock was halted. The post Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approv
FDA approves Reata's rare nervous-system drug amid questions about changing regulatory environment for neuroscience treatments
05:35pm, Tuesday, 28'th Feb 2023
The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.'s treatment for Friedreich's ataxia, a rare inherited disease that causes damage to the nervous system.
